274 related articles for article (PubMed ID: 35051898)
1. No difference in radiologic outcomes for natalizumab patients treated with extended interval dosing compared with standard interval dosing: Real-world evidence from MS PATHS.
Ryerson LZ; Naismith RT; Krupp LB; Charvet LE; Liao S; Fisher E; de Moor C; Williams JR; Campbell N
Mult Scler Relat Disord; 2022 Feb; 58():103480. PubMed ID: 35051898
[TBL] [Abstract][Full Text] [Related]
2. Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial.
Foley JF; Defer G; Ryerson LZ; Cohen JA; Arnold DL; Butzkueven H; Cutter G; Giovannoni G; Killestein J; Wiendl H; Smirnakis K; Xiao S; Kong G; Kuhelj R; Campbell N;
Lancet Neurol; 2022 Jul; 21(7):608-619. PubMed ID: 35483387
[TBL] [Abstract][Full Text] [Related]
3. sNFL applicability as additional monitoring tool in natalizumab extended interval dosing regimen for RRMS patients.
Valentino P; Malucchi S; Martire S; Bava CI; Capobianco MA; Bertolotto A
Mult Scler Relat Disord; 2022 Nov; 67():104176. PubMed ID: 36126541
[TBL] [Abstract][Full Text] [Related]
4. MRI activity and extended interval of Natalizumab dosing regimen: a multicentre Italian study.
De Mercanti SF; Signori A; Cordioli C; Signoriello E; Lus G; Bonavita S; Abbadessa G; Lavorgna L; Maniscalco GT; Curti E; Lorefice L; Cocco E; Nociti V; Mirabella M; Baroncini D; Mataluni G; Landi D; Petruzzo M; Lanzillo R; Gandoglia I; Laroni A; Frangiamore R; Sartori A; Cavalla P; Costantini G; Capra R; Sormani MP; Clerico M
J Neurol Sci; 2021 May; 424():117385. PubMed ID: 33770708
[TBL] [Abstract][Full Text] [Related]
5. Extended interval dosing of natalizumab in multiple sclerosis.
Zhovtis Ryerson L; Frohman TC; Foley J; Kister I; Weinstock-Guttman B; Tornatore C; Pandey K; Donnelly S; Pawate S; Bomprezzi R; Smith D; Kolb C; Qureshi S; Okuda D; Kalina J; Rimler Z; Green R; Monson N; Hoyt T; Bradshaw M; Fallon J; Chamot E; Bucello M; Beh S; Cutter G; Major E; Herbert J; Frohman EM
J Neurol Neurosurg Psychiatry; 2016 Aug; 87(8):885-9. PubMed ID: 26917698
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of natalizumab extended interval dosing.
Yamout BI; Sahraian MA; Ayoubi NE; Tamim H; Nicolas J; Khoury SJ; Zeineddine MM
Mult Scler Relat Disord; 2018 Aug; 24():113-116. PubMed ID: 29982107
[TBL] [Abstract][Full Text] [Related]
7. Progressive multifocal leukoencephalopathy with natalizumab extended or standard interval dosing in the United States and the rest of the world.
Dsilva L; McCarthy K; Lyons J; Cabigas B; Campbell N; Kong G; Adams B; Kuhelj R; Singhal P; Smirnakis K
Expert Opin Drug Saf; 2023; 22(10):995-1002. PubMed ID: 37272350
[TBL] [Abstract][Full Text] [Related]
8. Exploring the effects of extended interval dosing of natalizumab and drug concentrations on brain atrophy in multiple sclerosis.
Toorop AA; Noteboom S; Steenwijk MD; Gravendeel JW; Jasperse B; Barkhof F; Strijbis EM; Rispens T; Schoonheim MM; van Kempen ZL; Killestein J
Mult Scler; 2024 Feb; 30(2):266-271. PubMed ID: 38235514
[TBL] [Abstract][Full Text] [Related]
9. Healthcare resource utilization and costs for extended interval dosing of natalizumab in multiple sclerosis.
Moccia M; Loperto I; Santoni L; Masera S; Affinito G; Carotenuto A; Lanzillo R; Triassi M; Morra VB; Palladino R
Neurodegener Dis Manag; 2022 Jun; 12(3):109-116. PubMed ID: 35446149
[No Abstract] [Full Text] [Related]
10. Evaluation of natalizumab pharmacokinetics and pharmacodynamics with standard and extended interval dosing.
Foley JF; Goelz S; Hoyt T; Christensen A; Metzger RR
Mult Scler Relat Disord; 2019 Jun; 31():65-71. PubMed ID: 30939392
[TBL] [Abstract][Full Text] [Related]
11. Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing.
Ryerson LZ; Foley J; Chang I; Kister I; Cutter G; Metzger RR; Goldberg JD; Li X; Riddle E; Smirnakis K; Kasliwal R; Ren Z; Hotermans C; Ho PR; Campbell N
Neurology; 2019 Oct; 93(15):e1452-e1462. PubMed ID: 31515290
[TBL] [Abstract][Full Text] [Related]
12. Exploratory clinical efficacy and patient-reported outcomes from NOVA: A randomized controlled study of intravenous natalizumab 6-week dosing versus continued 4-week dosing for relapsing-remitting multiple sclerosis.
Ryerson LZ; Foley JF; Defer G; Cohen JA; Arnold DL; Butzkueven H; Cutter G; Giovannoni G; Killestein J; Wiendl H; Sinks S; Kuhelj R; Bodhinathan K; Lasky T
Mult Scler Relat Disord; 2023 Apr; 72():104561. PubMed ID: 36931078
[TBL] [Abstract][Full Text] [Related]
13. Real-World Effectiveness of Natalizumab Extended Interval Dosing in a French Cohort.
Pelle J; Briant AR; Branger P; Derache N; Arnaud C; Lebrun-Frenay C; Cohen M; Mondot L; De Seze J; Bigaut K; Collongues N; Kremer L; Ricard D; Bompaire F; Ohlmann C; Sallansonnet-Froment M; Ciron J; Biotti D; Pignolet B; Parienti JJ; Defer G
Neurol Ther; 2023 Apr; 12(2):529-542. PubMed ID: 36763307
[TBL] [Abstract][Full Text] [Related]
14. Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved?
Clerico M; De Mercanti SF; Signori A; Iudicello M; Cordioli C; Signoriello E; Lus G; Bonavita S; Lavorgna L; Maniscalco GT; Curti E; Lorefice L; Cocco E; Nociti V; Mirabella M; Baroncini D; Mataluni G; Landi D; Petruzzo M; Lanzillo R; Gandoglia I; Laroni A; Frangiamore R; Sartori A; Cavalla P; Costantini G; Sormani MP; Capra R
Neurotherapeutics; 2020 Jan; 17(1):200-207. PubMed ID: 31452081
[TBL] [Abstract][Full Text] [Related]
15. Does Extended Interval Dosing Natalizumab Preserve Effectiveness in Multiple Sclerosis? A 7 Year-Retrospective Observational Study.
Riancho J; Setien S; Sánchez de la Torre JR; Torres-Barquin M; Misiego M; Pérez JL; Castillo-Triviño T; Menéndez-García C; Delgado-Alvarado M
Front Immunol; 2021; 12():614715. PubMed ID: 33841397
[TBL] [Abstract][Full Text] [Related]
16. Clinical and Immunological Impact of Ocrelizumab Extended Interval Dosing in Multiple Sclerosis: A Single-Center, Real-World Experience.
Nasello M; Zancan V; Rinaldi V; Marrone A; Reniè R; Diamant S; Marconi M; Le Mura L; Salvetti M; Buscarinu MC; Bellucci G
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791391
[TBL] [Abstract][Full Text] [Related]
17. Is It Time for Ocrelizumab Extended Interval Dosing in Relapsing Remitting MS? Evidence from An Italian Multicenter Experience During the COVID-19 Pandemic.
Zanghì A; Avolio C; Signoriello E; Abbadessa G; Cellerino M; Ferraro D; Messina C; Barone S; Callari G; Tsantes E; Sola P; Valentino P; Granella F; Patti F; Lus G; Bonavita S; Inglese M; D'Amico E
Neurotherapeutics; 2022 Sep; 19(5):1535-1545. PubMed ID: 36036858
[TBL] [Abstract][Full Text] [Related]
18. Switch to ocrelizumab in MS patients treated with natalizumab in extended interval dosing at high risk of PML: A 96-week follow-up pilot study.
Santiago-Setien P; Barquín-Rego C; Hernández-Martínez P; Ezquerra-Marigomez M; Torres-Barquin M; Menéndez-Garcia C; Uriarte F; Jiménez-López Y; Misiego M; Sánchez de la Torre JR; Setien S; Delgado-Alvarado M; Riancho J
Front Immunol; 2023; 14():1086028. PubMed ID: 36817456
[TBL] [Abstract][Full Text] [Related]
19. Switching to ocrelizumab in RRMS patients at risk of PML previously treated with extended interval dosing of natalizumab.
Mancinelli CR; Scarpazza C; Cordioli C; De Rossi N; Rasia S; Turrini MV; Capra R
Mult Scler; 2021 Apr; 27(5):790-794. PubMed ID: 32749910
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic performance of brain MRI in pharmacovigilance of natalizumab-treated MS patients.
Wattjes MP; Wijburg MT; Vennegoor A; Witte BI; Roosendaal SD; Sanchez E; Liu Y; Martins Jarnalo CO; Richert ND; Uitdehaag BM; Barkhof F; Killestein J
Mult Scler; 2016 Aug; 22(9):1174-83. PubMed ID: 26564995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
